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INTRODUCTION
Several randomized trials have demonstrated the safety and 
effectiveness of trans-catheter aortic valve implantation (TAVI) 
in patients with symptomatic severe aortic stenosis who were 
at low- to high-risk for adverse outcomes during conventional 
surgical aortic valve replacement.1-7 Despite the wide expansion 
of indications for TAVI, however, the potential for various pro-
cedure-related complications still exists, including vascular/
bleeding events, stroke, permanent pacemaker implantation, 
emergent conversion to open-heart surgery, and acute coronary 
occlusion.2-9 Among these TAVI-related complications, acute or 
delayed coronary occlusion is a rare but devastating complica-
tion, with an overall mortality rate greater than 50%.10,11 Previ-
ous studies have reported that the anatomical predictors for 
acute coronary occlusion during TAVI are a low height (≤10 mm) 
for the ostium of coronary arteries from aortic annuls and a small 
aortic sinus of Valsalva (≤30 mm).10-13 The risk of acute coronary 
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occlusion may also depend on the type of TAVI valves used (e.g., 
self-expandable vs. balloon-expandable) and the conduct of 
TAVI in a native aortic valve or valve-in-valve context.10-13 In this 
study, we sought to evaluate the feasibility of self-expanding 
valves in patients with low coronary heights undergoing TAVI 
for symptomatic severe stenosis.
MATERIALS AND METHODS
Between 2015 and 2019, 276 consecutive patients underwent 
TAVI for symptomatic severe native aortic valve stenosis at our 
institute. Also, two patients underwent TAVI for severe valve-
in-valve stenosis during the same study period; however, these 
two patients were excluded from the analysis of this study. Among 
the 276 patients who underwent TAVI in the native aortic valve, 
multi-detector computed tomography (MDCT) was performed 
in 269 patients. The remaining seven patients did not undergo 
pre-TAVI MDCT because TAVI was performed in an emergent 
situation. Information on the aortic valve, coronary arteries, and 
vascular anatomy from the 269 patients was analyzed. Patients 
with low coronary heights were defined as those with coronary 
heights of 10 mm or less between the annular plane and the 
most inferior aspect of the coronary ostia during MDCT anal-
ysis.10-12 This study complied with the principles of the Decla-
ration of Helsinki and the study protocol was approved by the 
Institutional Review Board of Severance Hospital (IRB No: 
1-2009-0018, 1-2011-0099). Written informed consent was ob-
tained from all patients. For every patient, a multidisciplinary 
heart team including interventional cardiologists, imaging car-
diologists, cardiothoracic surgeons, and anesthesiologists made 
decisions regarding eligibility for TAVI, choice of vascular ap-
proach, and type of anesthesia. The choice of transcatheter aor-
tic valve type was made at the discretion of the operating inter-
ventional cardiologists. The implantation techniques for both 
valves have been described previously.14,15 Early safety outcomes 
(at 30 days) and follow-up clinical outcomes were analyzed ac-
cording to the Valve Academic Research Consortium-2 consen-
sus.16 The early safety outcomes included all-cause mortality, 
all stroke, life-threatening bleeding, acute kidney injury of stag-
es 2 or 3, acute coronary occlusion requiring intervention, ma-
jor vascular complications, and valve-related dysfunction re-
quiring repeat procedure.
Continuous variables are reported as means±standard devia-
tions. Categorical variables are reported as numbers (percentage). 
RESULTS
Among 269 patients who underwent TAVI for symptomatic se-
vere native aortic stenosis, 29 patients (10.8%) demonstrated 
low coronary heights ≤10 mm. The baseline clinical character-
istics of the patients whose coronary height was ≤10 mm and 
>10 mm are described in Table 1. In patients whose coronary 
heights were ≤10 mm, the mean age of the included patients 
was 80.6±5.5 years, and most patients were female (n=24 pa-
tients; 82.8%). Pre-TAVI echocardiographic and MDCT find-
ings for the patients whose coronary height was ≤10 mm and 
>10 mm are presented in Table 2. In patients whose coronary 
height ≤10 mm, the mean annulus area was 407.1±67.7 mm2, 
and the mean perimeter diameter was 71.6±6.5 mm. The mean 
coronary height was 8.9±1.2 mm in the left coronary artery and 
14.7±2.6 mm in the right coronary artery. Among the 29 pa-
tients with low coronary heights, the TAVI valve was delivered 
through the femoral artery under general anesthesia with the 
use of transesophageal echocardiography in 27 patients and 
Table 1. Baseline Clinical Characteristics
Total study population
n=269
Patients without a low 
coronary height
n=240




Age (yr) 81.5±5.6 81.6±5.6 80.6±5.5 0.352
Male 132 (49.1) 127 (52.9) 5 (17.2) <0.001
Follow-up duration (days) 438±363.7 422.4±352.8 553.8±425.4 0.121
STS-PROM score (%) 7.1±8.7 7.0±9.0 7.4±5.6 0.830
Hypertension 226 (84) 203 (84.6) 23 (79.3) 0.464
Diabetes mellitus 111 (41.3) 100 (41.7) 11 (37.9) 0.700
Coronary artery disease 164 (61) 147 (61.3) 17 (58.6) 0.784
Prior percutaneous coronary intervention 68 (25.3) 60 (25) 8 (27.6) 0.762
Prior acute myocardial infarction 28 (10.4) 24 (10) 4 (13.8) 0.528
Chronic obstructive airways disease 42 (15.6) 37 (15.4) 5 (17.2) 0.798
Prior cerebrovascular accident 53 (19.8) 50 (20.8) 3 (10.3) 0.203
Prior permanent pacemaker 5 (1.9) 4 (1.7) 1 (3.4) 0.502
Chronic kidney disease 138 (51.3) 124 (51.7) 14 (48.3) 0.730
STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality.
Data are presented as mean±standard deviation or n (%). 
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local anesthesia with sedation in two patients. Twenty-eight 
patients were treated with a self-expandable valve (CoreValve, 
Evolut R, or Evolut Pro; Medtronic, Minneapolis, MN, USA), 
and one patient was treated with a balloon-expandable valve 
(Sapien 3; Edwards Lifesciences, Irvine, CA, USA). Prophylac-
tic coronary protection with a guidewire, balloon, or stent prep-
ositioned down at-risk coronary arteries was not completed in 
all patients. No case of acute coronary occlusion occurred in 
any patient during TAVI. The effective orifice area of the aortic 
valve increased from 0.6±0.2 cm2 pre-TAVI to 2.0±0.5 cm2 post-
TAVI (Table 2). In 240 patients with a coronary height >10 mm, 
a self-expandable valve was used in 147 patients, a balloon-
expandable valve in 84 patients and a mechanically expanded 
valve (Lotus; Boston Scientific, Marlborough, MA, USA) in 9 
patients. Clinical outcomes seen during hospitalization and 
the follow-up period for the patients whose coronary height 
was ≤10 mm and >10 mm are presented in Table 3. In patients 
whose coronary height was ≤10 mm, life-threatening or major 
bleeding and minor bleeding occurred in 1 (3.4%) and 2 (6.9%) 
patients, respectively. There was no instance of all-cause death 
during hospitalization. Permanent pacemakers were implant-
ed in 6 patients (20.7%). The average follow-up duration after 
discharge was 553.8±425.4 days. Death occurred in 5 patients 
(17.9%) during follow-up (average of 553.8 days): the cause was 
non-cardiogenic in 4 patients and cardiogenic (aggravation of 
heart failure) in one patient. 
DISCUSSION 
Coronary artery obstruction is a rare but fatal intra- or post-TAVI 
complication that may occur in less than 1% of patients who 
undergo TAVI.10 The reported incidence of coronary obstruc-
tion differs according to valve type and procedure type: 0.34% 
in the context of a self-expandable valve vs. 0.81% in the con-
text of a balloon-expandable valve (p=0.023) and 0.62% in a na-
tive aortic valve case vs. 2.48% in a valve-in-valve case (p=0.045).10 
Delayed coronary obstruction might be divided into two types 
according to the timing of onset of this event after TAVI as early 
(<7 days) and late (>7 days) coronary obstruction,11 with cardiac 
arrest or ST-elevation myocardial infarction constituting the 
clinical presentation in early delayed coronary obstruction and 
stable or unstable angina constituting the clinical presentation 
in late delayed coronary obstruction.11 The potential mecha-
nism of early delayed coronary obstruction might be correlat-
ed with the displacement of a calcified native valve leaflet.10-12 
Table 2. Echocardiographic and Multi-Detector Computed Tomography Findings 
Total study population
n=269
Patients without a low 
coronary height
n=240




Multi-detector computed tomography 
Native aortic annulus
Area (mm2) 429.8±67.6 432.8±67.3 407.1±67.7 0.142
Perimeter (mm) 74.9±6.1 75.3±5.9 71.6±6.5 0.004
Minimum diameter (mm) 20.7±2.1 20.8±2 20.2±2.7 0.244
Mean diameter (mm) 23.7±2.0 23.9±2.0 22.7±2.1 0.005
Native aortic root 
Sinus of Valsalva diameter (mm) 31.6±3.5 32±3 28.3±4.9 <0.001
Sinotubular junction diameter (mm) 28.2±3.1 28.2±3.1 27.9±3.7 0.620
Height of right coronary artery (mm) 16.7±2.6 17.0±2.5 14.7±2.6 <0.001
Height of left coronary artery (mm) 13.5±2.7 14.0±2.3 8.9±1.2 <0.001
Pre-TAVI echocardiography 
Left ventricular ejection fraction (%) 59.8±15.2 59.9±15.4 58.8±13.8 0.712
Aortic valve
Peak pressure gradient (mm Hg) 81.0±26.5 79.3±26.2 95.2±25.0 0.002
Mean pressure gradient (mm Hg) 49.5±17.6 48.4±17.3 59.1±17.0 0.002
Mean aortic valve area (cm2) 0.7±0.2 0.7±0.2 0.6±0.2 0.007
Post-TAVI echocardiography 
Left ventricular ejection fraction (%) 61.8±14.1 61.8±14.5 62.3±10.8 0.832
Aortic valve
Peak pressure gradient (mm Hg) 19.5±9.2 19.3±9 21.0±10.8 0.368
Mean pressure gradient (mm Hg) 9.9±4.9 9.8±4.7 10.9±6.0 0.279
Effective orifice area (cm2) 2.0±0.53 2.1±0.53 2.0±0.5 0.321
TAVI, trans-catheter aortic valve implantation.
Data are presented as means±standard deviations. 
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The predominant mechanism of late delayed coronary obstruc-
tion might be linked to bioprosthetic valve endothelialization 
with some degree of obstruction or embolization of unknown 
thrombus.10-12 When coronary obstruction occurs following TAVI, 
percutaneous coronary intervention is the preferred treatment 
option.10 The literature suggests 30-day mortality rates reach 
50% in patients with coronary artery bypass graft surgery, 22.2% 
in patients with successful percutaneous coronary intervention, 
and 100% in patients without successful percutaneous coro-
nary intervention.10
Early coronary obstruction occurs more frequently in patients 
treated with a balloon-expandable valve than those treated with 
a self-expandable valve.10,17,18 A recent study reported that par-
tial obstruction and complete obstruction of the left coronary 
ostium on follow-up computed tomography occurred in 33.6% 
and 2.1% of patients, respectively, who underwent TAVI with 
balloon-expandable valve.19 The risk factors for early coronary 
obstruction were a narrow aortic sinus of Valsalva (<30 mm) and 
low coronary height (<10 mm).10-13 One German registry study 
with 86 patients who had low coronary heights (mean height 
of 6.4±1.1 mm) reported that coronary obstruction occurred in 
three patients: two of these individuals underwent a valve-in-
valve procedure and the third patient was treated with a Lotus 
valve.20 All patients except one with low coronary heights in the 
present study (8.9±1.2 mm) were successfully treated with 
self-expandable valves. There was no occurrence of acute cor-
onary occlusion even without prophylactic coronary protection 
of at-risk coronary arteries. 
Coronary protection and chimney stenting have been found 
to prevent coronary artery obstruction during TAVI.11,21,22 One 
recent study adopted chimney stenting for the prevention of 
coronary artery obstruction during TAVI in 60 (0.5%) of 12800 
TAVI procedures.21 Among these 60 patients, 42 patients (70%) 
underwent TAVI due to a degenerative surgical bioprosthesis. 
Ultimately, 3 patients (5%) died, 13 patients (21.6%) experienced 
myocardial infarction, and 14 patients (23.3%) exhibited car-
diogenic shock during 30 days of follow up.21 The proportion of 
the chimney coronary stent that protruded into the aorta com-
prised 49.7% of the total stent length.21 The presence of a pro-
truding chimney coronary stent between the TAVI valve and 
native coronary artery ostium might be involved with turbulent 
blood flow or hemodynamic deterioration in the aortic sinus 
of Valsalva and play a substantial role as a nidus for thrombus 
formation in the future. Therefore, a more prolonged duration 
of dual antiplatelet therapy or (single or dual) antiplatelet ther-
apy plus anticoagulant therapy might be required to prevent 
Table 3. Clinical Outcomes
Total study population
n=269
Patients without a low 
coronary height
n=240





Life-threatening or major bleeding 5 (1.9) 4 (1.7) 1 (3.4) 0.502
Minor bleeding 38 (14.1) 32 (13.3) 6 (20.7) 0.283
Acute kidney injury 40 (14.9) 35 (14.6) 5 (17.2) 0.711
Stage I 22 (8.2) 20 (8.4) 2 (6.9)
Stage II 6 (2.2) 5 (2.1) 1 (3.4)
Stage III 12 (4.5) 10 (4.2) 2 (6.9)
All-cause death 18 (6.7) 18 (7.5) 0 (0) 0.127
Cardiogenic death 11 (4.1) 11 (4.6) 0 (0) 0.239
Noncardiogenic death 7 (2.6) 7 (2.9) 0 (0) 0.351
Stroke 9 (3.4) 7 (2.9) 2 (6.9) 0.450
Myocardial infarction 1 (0.4) 1 (0.4) 0 (0) 0.727
Acute coronary obstruction 0 (0) 0 (0) 0 (0) -
New permanent pacemaker 34 (12.7) 28 (11.7) 6 (20.7) 0.170
Follow-up outcomes
All-cause death 24 (8.9) 19 (7.9) 5 (17.2) 0.096.
30-day cardiogenic death 1 (0.4) 1 (0.4) 0 (0) 0.728
30-day noncardiogenic death 1 (0.4) 0 (0) 1 (3.4) 0.004
1-year cardiogenic death 2 (0.7) 1 (0.4) 1 (3.4) 0.073
1-year noncardiogenic death 20 (7.4) 17 (7.1) 3 (10.3) 0.527
Myocardial infarction 0 (0) 0 (0) 0 (0) -
Coronary obstruction 0 (0) 0 (0) 0 (0) -
New permanent pacemaker 4 (1.6) 4 (1.9) 0 (0) 0.467
Re-hospitalization 18 (7.4) 16 (7.4) 2 (6.9) 0.955
Data are presented as n (%).
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thrombus formation in the coronary stent or TAVI valve. How-
ever, a prolonged duration of antiplatelet and/or anticoagulant 
therapy might translate to a subsequent increase in bleeding 
risk among patients treated with TAVI and chimney stent im-
plantation. The absence of coronary protection was the only 
predictor of 30-day death, myocardial infarction, and/or cardio-
genic shock in a recent study.21 Another study reported preven-
tive stent implantation across the coronary ostia was associated 
with good mid-term survival and a low rate of stent thrombo-
sis in patients who underwent TAVI and were at high risk for 
delayed coronary occlusion.23 Meanwhile, another novel ap-
proach, the bioprosthetic or native aortic scallop intentional 
laceration to prevent iatrogenic coronary artery obstruction 
(BASILICA) technique, was developed to prevent coronary ar-
tery obstruction in high-risk patients during TAVI.24 When us-
ing the BASILICA technique, equipment, such as an electro-
surgery pencil and electrosurgery generator for laceration, is 
required. In addition, this procedure includes many unfamil-
iar steps, and side effects of anatomical limitations and stroke 
have been reported.24
The favorable clinical outcomes and lack of acute coronary 
occlusion in the patients with low coronary heights treated with 
self-expandable valves in this study might be explained as fol-
lows. First, TAVI was performed exclusively in patients with na-
tive aortic valve stenosis and not in those with degenerative sur-
gical bioprosthesis stenosis. Second, because self-expandable 
valves have the capacity to retrieve the valve, we may check the 
possibility of acute coronary occlusion again immediately be-
fore complete deployment of the valve during the real TAVI pro-
cedure. Finally, the specific configuration of self-expandable 
valves with a concave appearance at the mid-portion of the 
valve provide more sufficient space with which to avoid acute 
coronary occlusion relative to balloon-expandable valves, which 
exhibit a flat appearance at the mid-portion of the valve. There-
fore, the use of self-expandable valves may be considered in 
patients with low coronary height for prevention of occurrence 
of acute coronary occlusion. Subsequent need for coronary pro-
tection may be determined according to aortographic findings 
during pre-dilation of aortic valve with balloon. When there 
are significant impairments of coronary blood flow, coronary 
protection may be required. Otherwise, coronary protection 
may not be necessary.
This study has several limitations. This was a single-center 
retrospective study, and the number of included patients was 
too small. There was also an insufficient number of control pa-
tients who were treated with balloon-expandable valves. MDCT 
analysis, such as leaflet length, calcification volume of leaflet, 
and virtual valve to coronary ostial distance, which can affect 
coronary obstruction, was insufficient in this study. There also 
may have been a limitation with adequate coronary access in 
future coronary events in patients receiving self-expandable 
valve implantation. 
In conclusion, 29 patients (10.8%) with low coronary heights 
were observed among TAVI candidates. The use of self-expand-
able valves may be feasible to promote successful TAVI with-
out acute coronary occlusion in patients with low coronary 
heights.
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